Concurrent medications have emerged as significant predictors of AKI in cancer patients, with noteworthy associations observed between AKI and the simultaneous use of diuretics, angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB) [16], and Renin–angiotensin–aldosterone system inhibitor (RAASi) treatment [19]. This evidence concerns the gene ACE and acute kidney injury.